{"id":"https://openalex.org/W24999251","doi":null,"title":"Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.","display_name":"Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.","publication_year":2011,"publication_date":"2011-10-01","ids":{"openalex":"https://openalex.org/W24999251","mag":"24999251","pmid":"https://pubmed.ncbi.nlm.nih.gov/22252576"},"language":"en","primary_location":{"id":"pmid:22252576","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22252576","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5050556099","display_name":"Harry Paul Erba","orcid":"https://orcid.org/0000-0003-1093-2189","observed_orcids":["https://orcid.org/0000-0003-1093-2189"]},"institutions":[{"id":"https://openalex.org/I27837315","display_name":"University of Michigan","ror":"https://ror.org/00jmfr291","country_code":"US","type":"education","lineage":["https://openalex.org/I27837315"]},{"id":"https://openalex.org/I4210114445","display_name":"Michigan Medicine","ror":"https://ror.org/01zcpa714","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210114445"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Harry P Erba","raw_affiliation_strings":["Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109, USA. hperba@med.umich.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109, USA. hperba@med.umich.edu","institution_ids":["https://openalex.org/I27837315","https://openalex.org/I4210114445"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046901718","display_name":"Dat C. Pham","orcid":"https://orcid.org/0009-0003-8473-8191","observed_orcids":["https://orcid.org/0009-0003-8473-8191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dat C Pham","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112106604","display_name":"Robert Anthony Zaiden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Zaiden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038365802","display_name":"H. A. Vu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ho Vu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5017707526","display_name":"Shawn Tai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shawn Tai","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.4217,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":{"value":0.64606073,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"9","issue":"10","first_page":"734","last_page":"45"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":1.0},{"id":"https://openalex.org/keywords/nilotinib","display_name":"nilotinib","score":0.9850000143051147},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":1.0},{"id":"https://openalex.org/keywords/imatinib","display_name":"imatinib","score":0.8880000114440918},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8830000162124634},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.8619999885559082},{"id":"https://openalex.org/keywords/newly-diagnosed-patients","display_name":"newly diagnosed patients","score":0.8479999899864197},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.8610000014305115},{"id":"https://openalex.org/keywords/bcr-abl-mutations","display_name":"BCR-ABL mutations","score":0.9120000004768372},{"id":"https://openalex.org/keywords/complete-cytogenetic-response","display_name":"complete cytogenetic response","score":0.9020000100135803},{"id":"https://openalex.org/keywords/major-molecular-response","display_name":"major molecular response","score":0.9359999895095825},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.503000020980835},{"id":"https://openalex.org/keywords/drug-safety-profile","display_name":"drug safety profile","score":0.48399999737739563}],"concepts":[{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.9928972125053406},{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.9723354578018188},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9464768171310425},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.8013213276863098},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.5729878544807434},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.533733069896698},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5332374572753906},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4763232171535492},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4392622113227844},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.43014034628868103},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.42449912428855896},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3308452367782593},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.08711168169975281},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068877","descriptor_name":"Imatinib Mesylate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069439","descriptor_name":"Dasatinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001549","descriptor_name":"Benzamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D015972","descriptor_name":"Gene Expression Regulation, Neoplastic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D016044","descriptor_name":"Fusion Proteins, bcr-abl","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:22252576","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22252576","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical advances in hematology & oncology : H&O","raw_type":"Journal Article"},{"id":"mag:24999251","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22252576","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":66,"referenced_works":["https://openalex.org/W977069352","https://openalex.org/W1716151440","https://openalex.org/W1928548710","https://openalex.org/W1965429870","https://openalex.org/W1965615377","https://openalex.org/W1978588805","https://openalex.org/W1980571402","https://openalex.org/W1981809014","https://openalex.org/W1981932456","https://openalex.org/W1982993780","https://openalex.org/W1983852790","https://openalex.org/W1987593147","https://openalex.org/W1990020715","https://openalex.org/W1995670055","https://openalex.org/W1997187693","https://openalex.org/W1998936478","https://openalex.org/W2009746825","https://openalex.org/W2011474502","https://openalex.org/W2014316424","https://openalex.org/W2016960626","https://openalex.org/W2021648831","https://openalex.org/W2021986444","https://openalex.org/W2028959752","https://openalex.org/W2039531591","https://openalex.org/W2046269728","https://openalex.org/W2057718276","https://openalex.org/W2057827171","https://openalex.org/W2058190985","https://openalex.org/W2061440903","https://openalex.org/W2069796323","https://openalex.org/W2084734126","https://openalex.org/W2091423586","https://openalex.org/W2097799776","https://openalex.org/W2097946794","https://openalex.org/W2107268345","https://openalex.org/W2108472756","https://openalex.org/W2109877587","https://openalex.org/W2117356576","https://openalex.org/W2117806883","https://openalex.org/W2120033838","https://openalex.org/W2124196948","https://openalex.org/W2126428160","https://openalex.org/W2131501125","https://openalex.org/W2135429827","https://openalex.org/W2143939343","https://openalex.org/W2146658081","https://openalex.org/W2152217218","https://openalex.org/W2156671039","https://openalex.org/W2157436488","https://openalex.org/W2158884958","https://openalex.org/W2160007211","https://openalex.org/W2160811827","https://openalex.org/W2166270808","https://openalex.org/W2168633862","https://openalex.org/W2216682316","https://openalex.org/W2261840157","https://openalex.org/W2510062058","https://openalex.org/W2549973967","https://openalex.org/W2552717129","https://openalex.org/W2557343987","https://openalex.org/W2558943357","https://openalex.org/W2566861500","https://openalex.org/W2593142701","https://openalex.org/W2594322701","https://openalex.org/W2979938835","https://openalex.org/W2992837203"],"related_works":["https://openalex.org/W1989516083","https://openalex.org/W1993459073","https://openalex.org/W2153151008","https://openalex.org/W2356397564","https://openalex.org/W4254461073","https://openalex.org/W2001289393","https://openalex.org/W1967109553","https://openalex.org/W2107503236","https://openalex.org/W2154952787","https://openalex.org/W2321213113"],"abstract_inverted_index":{"The":[0,60],"approval":[1,167],"of":[2,9,18,25,31,41,48,77,141,152,247,253],"imatinib":[3,32,49],"in":[4,98,102,118,130,158,224],"2001":[5],"changed":[6],"the":[7,16,22,28,52,75,99,109,125,139,225,241,272],"landscape":[8],"chronic":[10,159],"myeloid":[11],"leukemia":[12],"(CML)":[13],"management,":[14],"becoming":[15],"standard":[17],"care":[19,151],"and":[20,56,62,69,87,96,116,124,143,189,205,218,245],"improving":[21],"survival":[23],"rates":[24],"patients.":[26,105],"With":[27],"prevalent":[29],"use":[30,140,169],"worldwide,":[33],"it":[34],"was":[35,200,211],"observed":[36,212],"that":[37,233],"up":[38],"to":[39,45,197,249,263,270],"one-third":[40],"patients":[42,155,278],"are":[43,84,220],"resistant":[44],"or":[46],"intolerant":[47],"therapy,":[50],"fueling":[51],"search":[53],"for":[54,74,80,149,168,203,276],"safer":[55],"more":[57,63],"effective":[58],"agents.":[59,172],"newer":[61,255],"potent":[64],"tyrosine":[65],"kinase":[66],"inhibitors":[67],"nilotinib":[68,95,142,217],"dasatinib":[70,97,144,219],"were":[71],"first":[72],"indicated":[73],"treatment":[76],"imatinib-resistant/-intolerant":[78],"patients,":[79],"whom":[81],"these":[82,254],"agents":[83,163,174],"both":[85,162,216],"safe":[86],"efficacious.":[88],"More":[89],"recent":[90],"clinical":[91],"studies":[92],"have":[93,164,175,229],"examined":[94],"frontline":[100,150,171,226],"setting":[101],"newly":[103,153],"diagnosed":[104,154],"Data":[106],"reported":[107],"from":[108],"phase":[110],"III":[111],"ENESTnd":[112],"(Evaluating":[113],"Nilotinib":[114],"Efficacy":[115],"Safety":[117],"Clinical":[119],"Trials-Newly":[120],"Diagnosed":[121,134],"Patients)":[122],"study":[123],"DASISION":[126],"(Dasatinib":[127],"versus":[128],"Imatinib":[129],"Patients":[131],"with":[132,156,181,213,279],"Newly":[133],"Chronic-phase":[135],"CML)":[136],"trial":[137],"support":[138],"as":[145,170,183,238,257,259],"potential":[146],"new":[147],"standards":[148],"CML":[157],"phase.":[160],"Furthermore,":[161],"received":[165],"regulatory":[166],"These":[173],"demonstrated":[176],"significantly":[177,201],"superior":[178],"efficacy":[179],"compared":[180],"imatinib,":[182],"measured":[184],"by":[185],"complete":[186],"cytogenetic":[187],"response":[188,192],"major":[190],"molecular":[191],"rates.":[193],"In":[194],"addition,":[195],"progression":[196,210],"advanced":[198],"disease":[199],"lower":[202,209],"nilotinib,":[204],"a":[206],"trend":[207],"toward":[208],"dasatinib.":[214],"Although":[215],"generally":[221],"well":[222,258],"tolerated":[223],"setting,":[227],"they":[228],"different":[230],"safety":[231,243],"profiles":[232],"may":[234],"affect":[235],"their":[236,277],"selection":[237],"treatment.":[239],"Understanding":[240],"efficacy,":[242],"profiles,":[244],"patterns":[246],"resistance":[248],"various":[250],"BCR-ABL1":[251],"mutations":[252],"agents,":[256],"implementing":[260],"management":[261],"strategies":[262],"treat":[264],"adverse":[265],"events,":[266],"will":[267],"help":[268],"physicians":[269],"provide":[271],"best":[273],"therapy":[274],"options":[275],"CML.":[280]},"counts_by_year":[{"year":2019,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}